JP7064512B2 - キナーゼ阻害剤およびその使用 - Google Patents

キナーゼ阻害剤およびその使用 Download PDF

Info

Publication number
JP7064512B2
JP7064512B2 JP2019563596A JP2019563596A JP7064512B2 JP 7064512 B2 JP7064512 B2 JP 7064512B2 JP 2019563596 A JP2019563596 A JP 2019563596A JP 2019563596 A JP2019563596 A JP 2019563596A JP 7064512 B2 JP7064512 B2 JP 7064512B2
Authority
JP
Japan
Prior art keywords
disease
alkyl
cycloalkyl
compound according
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019563596A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020520924A5 (enExample
JP2020520924A (ja
Inventor
ハビエル・デ・ビセンテ・フィダルゴ
アンソニー・エー・エストラーダ
ジアンウェン・エー・フェン
ブライアン・フォックス
チンツァ・マリア・フランチーニ
クリストファー・アール・エイチ・ヘイル
チェン・フー
コリン・フィリップ・レズリー
マクシム・オシポフ
エレナ・セッラ
ザッカリー・ケー・スウィーニー
アルン・トーットゥンカラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Denali Therapeutics Inc
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of JP2020520924A publication Critical patent/JP2020520924A/ja
Publication of JP2020520924A5 publication Critical patent/JP2020520924A5/ja
Priority to JP2021146775A priority Critical patent/JP7241825B2/ja
Application granted granted Critical
Publication of JP7064512B2 publication Critical patent/JP7064512B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/04—Seven-membered rings having the hetero atoms in positions 1 and 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D517/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2019563596A 2017-05-17 2018-05-17 キナーゼ阻害剤およびその使用 Active JP7064512B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021146775A JP7241825B2 (ja) 2017-05-17 2021-09-09 キナーゼ阻害剤およびその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762507698P 2017-05-17 2017-05-17
US62/507,698 2017-05-17
US201862664895P 2018-04-30 2018-04-30
US62/664,895 2018-04-30
PCT/US2018/033266 WO2018213632A1 (en) 2017-05-17 2018-05-17 Kinase inhibitors and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021146775A Division JP7241825B2 (ja) 2017-05-17 2021-09-09 キナーゼ阻害剤およびその使用

Publications (3)

Publication Number Publication Date
JP2020520924A JP2020520924A (ja) 2020-07-16
JP2020520924A5 JP2020520924A5 (enExample) 2021-07-26
JP7064512B2 true JP7064512B2 (ja) 2022-05-10

Family

ID=64274744

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019563596A Active JP7064512B2 (ja) 2017-05-17 2018-05-17 キナーゼ阻害剤およびその使用
JP2021146775A Active JP7241825B2 (ja) 2017-05-17 2021-09-09 キナーゼ阻害剤およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021146775A Active JP7241825B2 (ja) 2017-05-17 2021-09-09 キナーゼ阻害剤およびその使用

Country Status (21)

Country Link
US (3) US11203600B2 (enExample)
EP (1) EP3624797A4 (enExample)
JP (2) JP7064512B2 (enExample)
KR (1) KR102638151B1 (enExample)
CN (3) CN110913858B (enExample)
AU (1) AU2018269743B2 (enExample)
BR (1) BR112019023918A2 (enExample)
CA (1) CA3063934A1 (enExample)
CL (1) CL2019003263A1 (enExample)
CO (1) CO2019012957A2 (enExample)
CR (1) CR20190566A (enExample)
DO (1) DOP2019000290A (enExample)
EC (1) ECSP19089214A (enExample)
IL (1) IL270648B2 (enExample)
MX (2) MX2019013645A (enExample)
MY (1) MY200328A (enExample)
PE (2) PE20241932A1 (enExample)
PH (1) PH12019550235A1 (enExample)
SG (1) SG10201913927VA (enExample)
TW (1) TWI794232B (enExample)
WO (1) WO2018213632A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220072019A1 (en) * 2018-10-19 2022-03-10 Disarm Therapeutics, Inc. Inhibitors of sarm1 in combination with nad+ or a nad+ precursor
IL291665B2 (en) * 2019-09-27 2025-07-01 Univ Texas Inhibitors of receptor interacting protein kinase i for the treatment of disease
TWI873290B (zh) 2020-02-13 2025-02-21 德商百靈佳殷格翰國際股份有限公司 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物
WO2021187605A1 (ja) * 2020-03-19 2021-09-23 田辺三菱製薬株式会社 含窒素複素環αシアノカルボニル化合物
TW202214617A (zh) 2020-06-02 2022-04-16 法商賽諾菲公司 作為ｒｉｐｋ１抑制劑之異㗁唑啶及其用途
KR200493347Y1 (ko) 2020-07-06 2021-03-17 박혜진 휴대가 용이한 마스크
BR112023016539A2 (pt) * 2021-02-19 2023-11-14 Kalvista Pharmaceuticals Ltd Inibidores do fator xiia
WO2022231928A1 (en) * 2021-04-27 2022-11-03 Merck Sharp & Dohme Llc Ripk1 inhibitors and methods of use
EP4329765A4 (en) * 2021-04-27 2025-06-11 Merck Sharp & Dohme LLC Phenylazepines as RIPK1 inhibitors and methods of using them
JP2024544533A (ja) 2021-11-11 2024-12-03 ジェンザイム・コーポレーション Ｒｉｐｋ１阻害剤としてのイソオキサゾリジン及びその使用
TW202417453A (zh) * 2022-07-25 2024-05-01 美商戴納立製藥公司 ４－（３，３－二氟－２，２－二甲基－丙醯基）－３，５－二氫－２ｈ－吡啶並［３，４－ｆ］［１，４］氧氮呯－９－甲腈的固體形式
US20240100065A1 (en) * 2022-08-23 2024-03-28 Genzyme Corporation Methods for treating receptor-interacting protein kinase 1-mediated diseases
TW202444357A (zh) * 2023-01-23 2024-11-16 美商健臻公司 ４－（３，３－二氟－２，２－二甲基－丙醯基）－３，５－二氫－２ｈ－吡啶并［３，４－ｆ］［１，４］氧氮呯－９－甲腈之藥品調配物
TW202515552A (zh) * 2023-06-27 2025-04-16 美商健臻公司 製備4-(3,3-二氟-2,2-二甲基-丙醯基)-3,5-二氫-2h-吡啶并[3,4-f][1,4]氧雜氮呯-9-腈之方法
CN120365288A (zh) * 2024-01-23 2025-07-25 南京天印健华医药科技有限公司 作为ripk1抑制剂的杂环化合物
CN120365287A (zh) * 2024-01-23 2025-07-25 南京天印健华医药科技有限公司 作为ripk1抑制剂的杂环化合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002026732A1 (en) 2000-09-27 2002-04-04 Ajinomoto Co.,Inc. Benzodiazepine derivative
WO2014146494A1 (zh) 2013-03-20 2014-09-25 中国科学院上海药物研究所 β-氨基羰基类化合物、其制备方法、药物组合物及其用途
US20160222028A1 (en) 2015-02-02 2016-08-04 Forma Therapeutics, Inc. 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3861187B2 (ja) * 1996-08-02 2006-12-20 住友精化株式会社 チアゼピン誘導体の製造方法
RU2456287C1 (ru) * 2011-05-20 2012-07-20 Николай Филиппович Савчук Стимуляторы секреции инкретиновых гормонов, способы их получения и применения
TWI549944B (zh) 2011-07-01 2016-09-21 吉李德科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
TWI648273B (zh) * 2013-02-15 2019-01-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類（三）
TWI730959B (zh) * 2015-05-19 2021-06-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺
EP3307739B1 (en) * 2015-06-15 2020-10-07 GlaxoSmithKline Intellectual Property Development Limited Nrf2 regulators

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002026732A1 (en) 2000-09-27 2002-04-04 Ajinomoto Co.,Inc. Benzodiazepine derivative
WO2014146494A1 (zh) 2013-03-20 2014-09-25 中国科学院上海药物研究所 β-氨基羰基类化合物、其制备方法、药物组合物及其用途
US20160222028A1 (en) 2015-02-02 2016-08-04 Forma Therapeutics, Inc. 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors
US20160221973A1 (en) 2015-02-02 2016-08-04 Forma Therapeutics, Inc. 3-aryl bicyclic [4,5,0] hydroxamic acids as hdac inhibitors

Also Published As

Publication number Publication date
AU2018269743B2 (en) 2024-01-11
US11203600B2 (en) 2021-12-21
BR112019023918A2 (pt) 2020-06-02
US20220041620A1 (en) 2022-02-10
CN119264073A (zh) 2025-01-07
CO2019012957A2 (es) 2020-05-29
TW201900618A (zh) 2019-01-01
JP7241825B2 (ja) 2023-03-17
MY200328A (en) 2023-12-20
KR102638151B1 (ko) 2024-02-16
EP3624797A1 (en) 2020-03-25
MX2019013645A (es) 2020-09-17
WO2018213632A1 (en) 2018-11-22
DOP2019000290A (es) 2020-03-15
ECSP19089214A (es) 2020-05-29
IL270648A (enExample) 2020-01-30
CN119285572A (zh) 2025-01-10
JP2020520924A (ja) 2020-07-16
US20250011338A1 (en) 2025-01-09
PE20200729A1 (es) 2020-07-23
IL270648B2 (en) 2024-03-01
CN110913858B (zh) 2024-09-24
TWI794232B (zh) 2023-03-01
CA3063934A1 (en) 2018-11-22
CR20190566A (es) 2020-06-14
EP3624797A4 (en) 2021-07-21
PE20241932A1 (es) 2024-09-24
US12129263B2 (en) 2024-10-29
JP2021193116A (ja) 2021-12-23
CN110913858A (zh) 2020-03-24
SG10201913927VA (en) 2020-03-30
IL270648B1 (en) 2023-11-01
PH12019550235A1 (en) 2020-07-20
KR20200006125A (ko) 2020-01-17
AU2018269743A1 (en) 2020-01-16
US20200087319A1 (en) 2020-03-19
MX2022010755A (es) 2022-09-23
CL2019003263A1 (es) 2020-04-17

Similar Documents

Publication Publication Date Title
JP7064512B2 (ja) キナーゼ阻害剤およびその使用
KR102442235B1 (ko) 융합된 펜타시클릭 이미다졸 유도체
TWI378101B (en) Pyridine derivatives and their use in the treatment of psychotic disorders
AU2020232026A1 (en) Carboxamide-pyrimidine derivatives as shp2 antagonists
AU2016280137B2 (en) Tricyclic compounds and their use as phosphodiesterase inhibitors
EP3166608A1 (en) Aminopyridazinone compounds as protein kinase inhibitors
KR20160144378A (ko) 브루톤 티로신 키나제 억제제로서 작용하는 폴리플루오로화 화합물
JP2016537369A (ja) カゼインキナーゼ１ｄ／ｅ阻害剤としての置換された４，５，６，７−テトラヒドロピラゾロ［１，５−ａ］ピラジン誘導体
TW201422624A (zh) 作爲ｊａｋ抑制劑之三環稠合噻吩衍生物
CN102985417A (zh) 作为jak1抑制剂的哌啶-4-基氮杂环丁烷衍生物
CN105431420A (zh) 二杂芳基化合物及其用途
KR20250117446A (ko) 피리미딘 함유 다중 융합 고리계 유도체 억제제, 이의 제조 방법과 응용
WO2015165341A1 (zh) 作为rho激酶抑制剂的异喹啉磺酰衍生物
JP2023538091A (ja) Ｂｔｋ阻害剤としての複素環式化合物
JP2021504380A (ja) Ｐｄｅ１阻害剤としての置換フラノピリミジン化合物
WO2024217348A1 (zh) Kif18a抑制剂及其制备方法和用途
JP2024501282A (ja) イミダゾ［１，２－ａ］ピリジニル誘導体と疾患の治療におけるその使用
JP2025530793A (ja) Ｅｇｆｒ阻害剤及びその使用
WO2025232650A1 (zh) Kif18a抑制剂及其制备方法和用途
CN115557946A (zh) 杂环内酰胺类化合物，包含其的药物组合物及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210511

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210511

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20210511

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210615

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210909

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211012

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220210

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220214

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220307

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220308

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220405

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220422

R150 Certificate of patent or registration of utility model

Ref document number: 7064512

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250